Patient demographics
| . | All patients, N = 246 . | CHOP alone, N = 11 . | CHOP-R,* N = 107 . | CHOP-RIT,* N = 128 . |
|---|---|---|---|---|
| Age, median (min, max), y | 54 (24, 82) | 57 (38, 76) | 55 (31, 81) | 53 (24, 82) |
| <60, n (%) | 175 (71) | 7 (64) | 74 (69) | 94 (73) |
| Male, n (%) | 140 (57) | |||
| Non-Hispanic, n (%) | 218 (89) | |||
| White, n (%) | 222 (90) | |||
| Performance status, n (%) | ||||
| 0 | 180 (73) | |||
| 1 | 50 (20) | |||
| 2 | 4 (2) | |||
| FL grade, n (%) | ||||
| I/II | 205 (83) | |||
| III | 39 (16) | |||
| B symptoms, n (%) | 61 (25) | |||
| Stage III-IV, n (%) | 242 (98) | 11 (100) | 105 (98) | 126 (98) |
| Bulky disease, n (%) | 57 (23) | 2 (18) | 19 (18) | 36 (28) |
| Elevated serum β2M, n (%) | 148 (60) | 3 (27) | 64 (60) | 81 (63) |
| LDH (U/I),†n (%) | ||||
| Normal | 181 (74) | 8 (73) | 80 (75) | 93 (73) |
| Elevated | 60 (24) | 3 (27) | 23 (21) | 34 (27) |
| Serum β2M and LDH,†n (%) | ||||
| Low | 79 (32) | 7 (64) | 30 (28) | 42 (33) |
| Medium | 118 (48) | 2 (18) | 60 (56) | 56 (44) |
| High | 44 (18) | 2 (18) | 13 (12) | 29 (23) |
| FLIPI risk,†n (%) | ||||
| Low | 68 (28) | 29 (27) | 39 (30) | |
| Intermediate | 105 (43) | 52 (49) | 53 (41) | |
| High | 62 (25) | 26 (24) | 36 (28) | |
| Early progression,‡ n (%) | 55 (22) | 6 (55) | 26 (24) | 23 (18) |
| 5-y PFS, n (%) | 161 (61) | 3 (27) | 66 (62) | 83 (65) |
| 5-y OS, n (%) | 213 (87) | 10 (91) | 98 (92) | 108 (84) |
| Progression/death, n (%) | 126 (51) | 9 (82) | 59 (55) | 58 (45) |
| Follow-up for PFS, median (min, max), mo | 89 (1, 173) | 24 (11, 151) | 86 (7, 173) | 95 (1, 157) |
| Follow-up for OS, median (min, max), mo | 114 (2, 177) | 135 (47, 177) | 116 (12, 175) | 111 (2, 175) |
| . | All patients, N = 246 . | CHOP alone, N = 11 . | CHOP-R,* N = 107 . | CHOP-RIT,* N = 128 . |
|---|---|---|---|---|
| Age, median (min, max), y | 54 (24, 82) | 57 (38, 76) | 55 (31, 81) | 53 (24, 82) |
| <60, n (%) | 175 (71) | 7 (64) | 74 (69) | 94 (73) |
| Male, n (%) | 140 (57) | |||
| Non-Hispanic, n (%) | 218 (89) | |||
| White, n (%) | 222 (90) | |||
| Performance status, n (%) | ||||
| 0 | 180 (73) | |||
| 1 | 50 (20) | |||
| 2 | 4 (2) | |||
| FL grade, n (%) | ||||
| I/II | 205 (83) | |||
| III | 39 (16) | |||
| B symptoms, n (%) | 61 (25) | |||
| Stage III-IV, n (%) | 242 (98) | 11 (100) | 105 (98) | 126 (98) |
| Bulky disease, n (%) | 57 (23) | 2 (18) | 19 (18) | 36 (28) |
| Elevated serum β2M, n (%) | 148 (60) | 3 (27) | 64 (60) | 81 (63) |
| LDH (U/I),†n (%) | ||||
| Normal | 181 (74) | 8 (73) | 80 (75) | 93 (73) |
| Elevated | 60 (24) | 3 (27) | 23 (21) | 34 (27) |
| Serum β2M and LDH,†n (%) | ||||
| Low | 79 (32) | 7 (64) | 30 (28) | 42 (33) |
| Medium | 118 (48) | 2 (18) | 60 (56) | 56 (44) |
| High | 44 (18) | 2 (18) | 13 (12) | 29 (23) |
| FLIPI risk,†n (%) | ||||
| Low | 68 (28) | 29 (27) | 39 (30) | |
| Intermediate | 105 (43) | 52 (49) | 53 (41) | |
| High | 62 (25) | 26 (24) | 36 (28) | |
| Early progression,‡ n (%) | 55 (22) | 6 (55) | 26 (24) | 23 (18) |
| 5-y PFS, n (%) | 161 (61) | 3 (27) | 66 (62) | 83 (65) |
| 5-y OS, n (%) | 213 (87) | 10 (91) | 98 (92) | 108 (84) |
| Progression/death, n (%) | 126 (51) | 9 (82) | 59 (55) | 58 (45) |
| Follow-up for PFS, median (min, max), mo | 89 (1, 173) | 24 (11, 151) | 86 (7, 173) | 95 (1, 157) |
| Follow-up for OS, median (min, max), mo | 114 (2, 177) | 135 (47, 177) | 116 (12, 175) | 111 (2, 175) |
CHOP-R, 6 cycles of CHOP chemotherapy at 3-week intervals with 6 doses of rituximab; CHOP-RIT, 6 cycles of CHOP followed by consolidation with iodine 131I tositumomab radioimmunotherapy.
LDH is not available from 5 patients, 4 on CHOP-R, and 1 on CHOP-RIT; FLIPI risk is not available from 11 patients, all on CHOP alone.
Early progression is defined as progression or death within 2 years after registration.